Want to see LADX full AI Analyst Report?
LadRx (LADX) Stock Price & Analysis
LADX Stock Chart & Stats
- Day’s Range
- $0.01 - $0.01
- 52-Week Range
- $0.00 - $0.75
- Previous Close
- $0.01
- Volume
- 1
- Average Volume (3M)
- 240
- Market Cap
- $5,446
- Enterprise Value
- -$153.97B
- Total Cash (Recent Filing)
- $206.95K
- Total Debt (Recent Filing)
- $0
- Price to Earnings (P/E)
- 0.0
- Beta
- -2114.03
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Technology Platforms
LadRx's focus on proprietary technology platforms provides a competitive edge in developing unique cancer therapeutics, potentially leading to successful commercialization and partnerships.
Partnership Opportunities
LadRx's strategy of forming partnerships and licensing agreements with larger pharmaceutical companies can enhance its market reach and provide necessary financial support for R&D.
No Debt
The absence of debt provides LadRx with some financial flexibility, allowing the company to focus on strategic investments and partnerships without the burden of interest obligations.
Bears Say
Negative Equity
Negative equity suggests that LadRx is facing financial distress, which could hinder its ability to invest in R&D and commercialize its drug candidates effectively.
Lack Of Revenue
The absence of revenue generation highlights the challenge LadRx faces in commercializing its projects, which is critical for sustaining operations and achieving profitability.
Board Member Resignation
The resignation of a board member can signal potential governance issues or strategic disagreements, impacting investor confidence and long-term strategic direction.
LadRx News
LADX FAQ
What was LadRx’s price range in the past 12 months?
What is LadRx’s market cap?
When is LadRx’s upcoming earnings report date?
How were LadRx’s earnings last quarter?
Is LadRx overvalued?
Does LadRx pay dividends?
What is LadRx’s EPS estimate?
How many shares outstanding does LadRx have?
What happened to LadRx’s price movement after its last earnings report?
Which hedge fund is a major shareholder of LadRx?
What is the TipRanks Smart Score and how is it calculated?
Company Description
LadRx
LadRx Corporation, a biopharmaceutical company, engages in research and development of chemotherapeutic drugs for solid tumors in the United States. The company offers linker activated drug releases (LADR) technology, a platform consists of an organic backbone that is attached to a chemotoxic agent that targets and delivers the chemotoxic agent to the tumor environment and release within the tumor. Its lead candidates comprising LADRs 7, 8, 9, and 10 with novel derivatives of the auristatin and maytansinoid drug targeting tumors; and aldoxorubicin, which is in phase II clinical development for the treatment of pancreatic cancer. In addition, the company develops albumin companion diagnostic (ACDx) to identify patients with cancer that benefits from treatment with the four LADR lead candidates. The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. The company was incorporated in 1985 and is headquartered in Los Angeles, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jorge Kuri Slim
- Employees
- 2
- Website
- www.ladrxcorp.com
- Address
- 11726 San Vicente Boulevard, Los Angeles, CA, 90049, US
LadRx (LADX) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 8 | 1 | 10 |
| Technical Analysis | 4 | 1 | 2 |
| Moving Averages | 4 | 0 | 8 |



